X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6257) 6257
Publication (586) 586
Book Review (415) 415
Conference Proceeding (16) 16
Book Chapter (8) 8
Magazine Article (5) 5
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5810) 5810
pyrazines - pharmacology (4517) 4517
humans (3484) 3484
animals (3241) 3241
male (2083) 2083
bortezomib (1889) 1889
boronic acids - pharmacology (1476) 1476
rats (1315) 1315
female (1269) 1269
pharmacology & pharmacy (1192) 1192
mice (1171) 1171
pyrazines - therapeutic use (1049) 1049
antineoplastic agents - pharmacology (995) 995
oncology (972) 972
cell line, tumor (952) 952
apoptosis - drug effects (817) 817
apoptosis (789) 789
pyrazines - administration & dosage (726) 726
pyrazines - chemistry (690) 690
dose-response relationship, drug (637) 637
chemistry, medicinal (625) 625
cancer (598) 598
middle aged (581) 581
adult (524) 524
pyrazines - chemical synthesis (523) 523
proteasome inhibitors (518) 518
biochemistry & molecular biology (507) 507
rats, sprague-dawley (498) 498
structure-activity relationship (488) 488
protease inhibitors - pharmacology (467) 467
boronic acids - therapeutic use (454) 454
multiple myeloma - drug therapy (453) 453
cell proliferation - drug effects (418) 418
expression (403) 403
aged (402) 402
hematology (390) 390
in vitro techniques (375) 375
sitagliptin phosphate (375) 375
drug synergism (371) 371
activation (360) 360
analysis (347) 347
research (345) 345
antineoplastic agents - therapeutic use (339) 339
multiple myeloma (334) 334
boronic acids - administration & dosage (321) 321
multiple-myeloma (319) 319
amiloride - pharmacology (318) 318
time factors (318) 318
pyrazines (309) 309
article (307) 307
cells, cultured (307) 307
cell biology (305) 305
pyrazines - adverse effects (305) 305
pyrazines - pharmacokinetics (298) 298
abridged index medicus (297) 297
nf-kappa-b (295) 295
proteasome endopeptidase complex - metabolism (285) 285
cell survival - drug effects (282) 282
cell line (281) 281
proteins (274) 274
signal transduction - drug effects (274) 274
molecular structure (272) 272
cells (271) 271
triazoles - pharmacology (267) 267
disease models, animal (258) 258
chemistry, organic (252) 252
treatment outcome (252) 252
in-vitro (241) 241
multiple myeloma - pathology (239) 239
pyrazines - metabolism (239) 239
phosphorylation (231) 231
tetramethylpyrazine (231) 231
therapy (231) 231
blotting, western (229) 229
endocrinology & metabolism (226) 226
tumor cells, cultured (224) 224
inhibition (223) 223
nf-kappa b - metabolism (223) 223
enzyme inhibitors - pharmacology (222) 222
imidazoles - pharmacology (217) 217
care and treatment (216) 216
diabetes mellitus, type 2 - drug therapy (216) 216
xenograft model antitumor assays (212) 212
antineoplastic combined chemotherapy protocols - therapeutic use (209) 209
pyridines - pharmacology (209) 209
kinetics (208) 208
sodium - metabolism (204) 204
health aspects (201) 201
rats, wistar (200) 200
drug therapy (199) 199
in-vivo (199) 199
chemotherapy (198) 198
administration, oral (192) 192
sitagliptin (188) 188
drug resistance, neoplasm (184) 184
multiple myeloma - metabolism (181) 181
signal transduction (181) 181
medicine & public health (180) 180
mice, inbred c57bl (180) 180
proteasome inhibitor bortezomib (175) 175
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5705) 5705
Chinese (291) 291
Japanese (65) 65
German (53) 53
French (35) 35
Italian (33) 33
Polish (31) 31
Russian (31) 31
Spanish (10) 10
Hungarian (8) 8
Czech (2) 2
Portuguese (2) 2
Romanian (2) 2
Slovak (2) 2
Dutch (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Cell, ISSN 1535-6108, 09/2012, Volume 22, Issue 3, pp. 345 - 358
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting... 
DEUBIQUITINATING ENZYME | INACTIVATION | PROTEIN | THERAPY | ONCOLOGY | MDM2 | DEGRADATION | MECHANISMS | HAUSP | CANCER | P53 REGULATION | CELL BIOLOGY | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Molecular Sequence Data | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Thalidomide - pharmacology | Boronic Acids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Protease Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Multiple Myeloma - enzymology | Protease Inhibitors - therapeutic use | Proto-Oncogene Proteins c-mdm2 - metabolism | Ubiquitin Thiolesterase - antagonists & inhibitors | Bortezomib | Cyclin-Dependent Kinase Inhibitor p21 - antagonists & inhibitors | Thiophenes - pharmacology | Random Allocation | Mice, SCID | Ubiquitin Thiolesterase - genetics | Xenograft Model Antitumor Assays | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Mice | Thalidomide - therapeutic use | Pyrazines - pharmacology | Ubiquitin-Specific Peptidase 7 | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Medical colleges | Dexamethasone | Proteases | Analysis | Multiple myeloma | Lymphomas | Apoptosis | Index Medicus
Journal Article
Psychopharmacology, ISSN 0033-3158, 7/2013, Volume 228, Issue 2, pp. 271 - 282
The nucleus accumbens (NAc) is a site critical for the actions of many drugs of abuse. Psychoactive compounds, such as N-methyl-d-aspartate receptor (NMDAR)... 
High frequency oscillations | Gamma | Neurosciences | Biomedicine | Accumbens | Rat | Local field potentials | Serotonin receptor | Lysergic acid diethylamide | Pharmacology/Toxicology | Psychiatry | Hallucinogens | FREELY MOVING RATS | PSYCHIATRY | NEUROSCIENCES | PREFRONTAL CORTEX | PHENCYCLIDINE | ANTIPSYCHOTIC-DRUGS | I-125 DOI | NMDA RECEPTOR HYPOFUNCTION | PHARMACOLOGY & PHARMACY | LSD | STRIATAL NEURONS | FIELD POTENTIALS | BRAIN | Piperazines - administration & dosage | Rats, Wistar | Amphetamines - pharmacology | Nucleus Accumbens - metabolism | Pyrazines - administration & dosage | Male | Amphetamines - administration & dosage | Serotonin Receptor Agonists - pharmacology | Dose-Response Relationship, Drug | Lysergic Acid Diethylamide - administration & dosage | Receptor, Serotonin, 5-HT2A - drug effects | Methylamines - pharmacology | Hallucinogens - administration & dosage | Hallucinogens - pharmacology | Bridged Bicyclo Compounds - pharmacology | Injections, Intraperitoneal | Methylamines - administration & dosage | Rats | Bridged Bicyclo Compounds - administration & dosage | Serotonin Antagonists - pharmacology | Piperazines - pharmacology | Animals | Lysergic Acid Diethylamide - pharmacology | Ketamine - pharmacology | Nucleus Accumbens - drug effects | Pyrazines - pharmacology | Receptor, Serotonin, 5-HT2A - metabolism | Serotonin Receptor Agonists - administration & dosage | Nucleus accumbens | Brain | Physiological aspects | Hallucinogenic drugs | Dosage and administration | Health aspects | Electric properties | Rodents | Psychopharmacology | Index Medicus | Original Investigation
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 05/2002, Volume 277, Issue 19, pp. 16639 - 16647
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2009, Volume 8, Issue 7, pp. 1974 - 1984
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 10/2010, Volume 285, Issue 43, pp. 33520 - 33528
Although gamma-tocotrienol (T3), a vitamin E isolated primarily from palm and rice bran oil, has been linked with anticancer activities, the mechanism of this... 
MULTIPLE-MYELOMA | ACTIVATION | INHIBITION | CANCER CELLS | INDUCED APOPTOSIS | SRC | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENE-PRODUCTS | TRANSCRIPTION | FACTOR-KAPPA-B | NATURAL VITAMIN-E | Neoplasms - metabolism | Inhibitor of Apoptosis Proteins - genetics | Humans | Vitamin E - analogs & derivatives | G1 Phase - drug effects | Thalidomide - pharmacology | Neoplasm Proteins - metabolism | Protein Tyrosine Phosphatase, Non-Receptor Type 6 - biosynthesis | Janus Kinase 1 - metabolism | Chromans - pharmacology | Neoplasms - genetics | Janus Kinase 1 - genetics | Janus Kinase 2 - metabolism | gamma-Tocopherol - pharmacology | src-Family Kinases - metabolism | Enzyme Induction - drug effects | Antineoplastic Agents - pharmacology | G1 Phase - genetics | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - genetics | Gene Expression Regulation, Neoplastic - genetics | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Inhibitor of Apoptosis Proteins - biosynthesis | Bortezomib | Gene Silencing | Janus Kinase 2 - genetics | Angiogenesis Inhibitors - pharmacology | Antioxidants - pharmacology | Protein Tyrosine Phosphatase, Non-Receptor Type 6 - genetics | Neoplasms - drug therapy | Animals | Mice | RNA, Small Interfering | Pyrazines - pharmacology | src-Family Kinases - genetics | Apoptosis | Boronic Acids - pharmacology | Vitamin E - pharmacology | Index Medicus | Molecular Bases of Disease | STAT Transcription Factor | Signal Transduction | Tocotrienol | Src | Jak Kinase | Tyrosine-protein Phosphatase (Tyrosine Phosphatase)
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 07/2013, Volume 98, Issue 7, pp. E1163 - E1172
Context: Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potent strategy to increase glucose-dependent insulinotropic polypeptide and glucagon like peptide 1... 
APOPTOSIS | HUMAN PANCREATIC-ISLETS | METABOLIC SYNDROME | HYPERGLYCEMIA | ALPHA-CELLS | GLUCOSE | ENDOCRINOLOGY & METABOLISM | RECEPTOR EXPRESSION | RANDOMIZED CONTROLLED-TRIAL | BI 1356 | DIPEPTIDYL PEPTIDASE-IV | Palmitic Acid - metabolism | Dipeptidyl Peptidase 4 - metabolism | Antioxidants - chemistry | Dipeptidyl Peptidase 4 - chemistry | Humans | Interleukin 1 Receptor Antagonist Protein - genetics | Peptide Fragments - pharmacology | Interleukin-1beta - genetics | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Insulin-Secreting Cells - metabolism | Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors | Glucagon-Like Peptide 1 - agonists | Interleukin-1beta - metabolism | Interleukin 1 Receptor Antagonist Protein - metabolism | Purines - antagonists & inhibitors | Linagliptin | Interleukin 1 Receptor Antagonist Protein - pharmacology | Sitagliptin Phosphate | Insulin Secretion | Interleukin-1beta - antagonists & inhibitors | Recombinant Proteins - metabolism | Cell Survival - drug effects | Recombinant Proteins - antagonists & inhibitors | Cytokines - metabolism | Glucagon-Like Peptide 1 - metabolism | Purines - pharmacology | Tissue Culture Techniques | Dipeptidyl-Peptidase IV Inhibitors - chemistry | Glucagon-Like Peptide 1 - chemistry | Antioxidants - pharmacology | Recombinant Proteins - pharmacology | Insulin-Secreting Cells - immunology | Triazoles - pharmacology | Insulin - metabolism | Insulin-Secreting Cells - drug effects | Drug Inverse Agonism | Protein Stability - drug effects | Pyrazines - pharmacology | Quinazolines - pharmacology | Quinazolines - antagonists & inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 06/2013, Volume 73, Issue 12, pp. 3683 - 3691
Replication stress and DNA damage activate the ATR-Chk1 checkpoint signaling pathway that licenses repair and cell survival processes. In this study, we... 
CHECKPOINT KINASE 1 | IN-VITRO | ONCOLOGY | XANTHINE DERIVATIVES | DNA-DAMAGE RESPONSE | PROTEIN-KINASE | TUMOR-CELLS | MYELOGENOUS LEUKEMIA-CELLS | RADIOSENSITIZING AGENT | MAMMALIAN-CELLS | CHK1 INHIBITOR | Protein Kinases - metabolism | Protein Kinases - genetics | Humans | Ovarian Neoplasms - pathology | Cell Survival - genetics | Deoxycytidine - pharmacology | Immunoblotting | Sulfones - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | RNA Interference | BRCA1 Protein - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Phosphorylation - drug effects | cdc25 Phosphatases - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Cell Survival - drug effects | Topotecan - pharmacology | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Signal Transduction - genetics | cdc25 Phosphatases - genetics | Ataxia Telangiectasia Mutated Proteins | Cisplatin - pharmacology | Pyrimidines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerases - metabolism | BRCA2 Protein - metabolism | Signal Transduction - drug effects | Cell Line, Tumor | Benzimidazoles - pharmacology | Checkpoint Kinase 1 | Pyrazines - pharmacology | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Index Medicus | homologous recombination | ovarian cancer | Poly(ADP-ribose) polymerase | veliparib | gemcitabine | BRCA1 | cisplatin | BRCA2 | topotecan
Journal Article
Neuropharmacology, ISSN 0028-3908, 04/2014, Volume 79, pp. 127 - 135
Journal Article
Psychoneuroendocrinology, ISSN 0306-4530, 2015, Volume 55, pp. 81 - 93
Highlights • Novelty stress suppressed food intake in aged male mice markedly compared with aged female. • 5-HT2C R+ and c-Fos+ cells in the PVN was increased... 
Endocrinology & Metabolism | Psychiatry | Aged | Gender differences | Rikkunshito | Novelty stress | 5-HT2CR | Food intake | 5-HT | MESSENGER-RNA EXPRESSION | C-FOS | PSYCHIATRY | FOOD-INTAKE | LATE-LIFE | NOVELTY-INDUCED HYPOPHAGIA | ELEVATED PLUS-MAZE | OVARIECTOMIZED RATS | NEUROSCIENCES | FEMALE RATS | ENDOCRINOLOGY & METABOLISM | SEX-DIFFERENCES | PITUITARY-ADRENAL AXIS | Paraventricular Hypothalamic Nucleus - physiology | Anorexia | Age Factors | Nitriles - pharmacology | Aromatase Inhibitors - pharmacology | Receptor, Serotonin, 5-HT2C - metabolism | Male | Serotonin 5-HT2 Receptor Agonists - pharmacology | RNA, Messenger - metabolism | Brain - physiology | Brain - metabolism | Receptor, Serotonin, 5-HT2C - physiology | Female | Indoles - pharmacology | Phenols - pharmacology | Pyrazoles - pharmacology | Ghrelin - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Serotonin 5-HT2 Receptor Antagonists - pharmacology | Piperazines - pharmacology | Feeding Behavior - physiology | Feeding Behavior - drug effects | Brain - drug effects | Ghrelin - metabolism | Triazoles - pharmacology | Paraventricular Hypothalamic Nucleus - drug effects | Animals | Aminopyridines - pharmacology | Paraventricular Hypothalamic Nucleus - metabolism | Sex Factors | Stress, Psychological | Corticosterone - metabolism | Feeding Behavior - psychology | Mice | Receptor, Serotonin, 5-HT2C - genetics | Pyrazines - pharmacology | Receptors, Estrogen - physiology | Serotonin | Index Medicus
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 12/2012, Volume 696, Issue 1-3, pp. 194 - 202
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been demonstrated to improve glycemic control, in particular postprandial hyperglycemic control, in patients... 
Type 2 diabetes | Glucagon-like peptide-1 | Postprandial hyperglycemia | Teneligliptin | Dyslipidemia | Dipeptidyl peptidase-4 | MYOCARDIAL-INFARCTION | ENDOTHELIAL DYSFUNCTION | PRECLINICAL PROFILE | ISCHEMIC-HEART-DISEASE | IMPROVED GLUCOSE-TOLERANCE | IV INHIBITOR | CARDIOVASCULAR-DISEASE | BETA-CELL DYSFUNCTION | PHARMACOLOGY & PHARMACY | SLOW-BINDING INHIBITOR | Hypertriglyceridemia - drug therapy | Pyrazoles - therapeutic use | Nitriles - pharmacology | Rats, Wistar | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Dipeptidyl Peptidase 4 - blood | Glucagon-Like Peptide 1 - blood | Male | Insulin - blood | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Hyperglycemia - drug therapy | Pyrrolidines - pharmacology | Sitagliptin Phosphate | Thiazolidines - pharmacology | Adamantane - analogs & derivatives | Pyrazoles - pharmacology | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Blood Glucose - analysis | Rats | Hypolipidemic Agents - pharmacology | Hypertriglyceridemia - blood | Hypoglycemic Agents - pharmacology | Thiazolidines - therapeutic use | Rats, Zucker | Triazoles - pharmacology | Animals | Hyperglycemia - blood | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Pyrazines - pharmacology | Hyperglycemia | Peptides | Triglycerides | Glucose | Fatty acids | Dextrose | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 783 - 794
Journal Article